fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Penicillin v (potassium)

Form:

4 of 4 products shown

2 general benefit · 2 not a benefit

PEN V-K · DIN 00642215 · 300 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
PEN V-K · DIN 00642215 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Daily cost (source): $0.7492 Health Canada: Marketed since 2014-09-05 · brand PEN-VK · ATC J01CE02 PHENOXYMETHYLPENICILLIN · form Tablet · route Oral · ingredients PENICILLIN V POTASSIUM 300 MG · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PEN V-K: Formulary list price $0.19 per unit (the source does not state the unit; exact figure $0.1873). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00642215)

Source record
DIN 00642215: PEN V-K Raw flags: sec3=Y Item: 081216034; group id 29; item number 0061; lccId None; manufacturer id AAP Source form: Tab; strength: 300mg Recorded listing: General benefit Source prices (unrounded): $0.1873; ministry $0.1873 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00642215 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6421
Interchangeable products
PVF-K 500 · DIN 00248843 · not recorded
Shortage status: resolved shortage (ended May 12, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00642215
Shortage record checked October 6, 2026

Apo-Pen V-K · DIN 00642223 · 25 mg/mL · oral liquid

General benefit; Health Canada lists this DIN as Cancelled post market since 2024-10-24 — choose a marketed DIN from the same-category list.Discontinued October 24, 2024 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-10-24 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-10-24 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Pen V-K · DIN 00642223 Manufacturer: Apotex Inc.; listing date 1996-10-01 Daily cost (source): $1.0700 Health Canada: Cancelled post market since 2024-10-24 · brand APO PEN VK · ATC J01CE02 PHENOXYMETHYLPENICILLIN · form Powder for solution · route Oral · ingredients PENICILLIN V POTASSIUM 125 MG/5ML · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Pen V-K: Formulary list price $0.05 per unit (the source does not state the unit; exact figure $0.0535). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00642223)

Source record
DIN 00642223: Apo-Pen V-K Raw flags: sec3=Y Item: 081216035; group id 29; item number 0060; lccId None; manufacturer id APX Source form: O/L; strength: 25mg/mL Recorded listing: General benefit Source prices (unrounded): $0.0535; ministry $0.0535 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00642223 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6422
Interchangeable products
Nadopen-V · DIN 00018635 · not recorded
Shortage status: resolved shortage (ended March 8, 2019); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00642223
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since October 24, 2024 — choose a marketed DIN from the same-category list.

Nadopen-V · DIN 00018635 · 25 mg/mL · oral liquid

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-08-25 — choose a marketed DIN from the same-category list.Discontinued August 25, 2006 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-08-25 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2006-08-25 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Nadopen-V · DIN 00018635 Manufacturer: Nadeau Laboratory Ltd.; listing date 1996-10-01 Daily cost (source): $1.0700 Health Canada: Cancelled post market since 2006-08-25 · brand NADOPEN V 200 · ATC J01CE02 PHENOXYMETHYLPENICILLIN · form Powder for solution · route Oral · ingredients PENICILLIN V POTASSIUM 40000 UNIT/ML · company Lioh inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Nadopen-V: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00018635)

Source record
DIN 00018635: Nadopen-V Raw flags: notABenefit=Y, sec3=Y Item: 081216035; group id 29; item number 0060; lccId None; manufacturer id NDA Source form: O/L; strength: 25mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00018635 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1512
Interchangeable products
Apo-Pen V-K · DIN 00642223 · $0.0535
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00018635
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 25, 2006 — choose a marketed DIN from the same-category list.

PVF-K 500 · DIN 00248843 · 300 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1998-04-21 — choose a marketed DIN from the same-category list.Discontinued April 21, 1998 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1998-04-21 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 1998-04-21 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
PVF-K 500 · DIN 00248843 Manufacturer: Merck Frosst Canada & Cie, Merck Frosst Canada & Co.; listing date 1996-10-01 Daily cost (source): $0.7492 Health Canada: Cancelled post market since 1998-04-21 · brand PVF K500TAB · ATC J01CE02 PHENOXYMETHYLPENICILLIN · form Tablet · route Oral · ingredients PENICILLIN V (PENICILLIN V POTASSIUM) 500000 UNIT/TAB · company Merck frosst canada & cie, merck frosst canada & co. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PVF-K 500: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00248843)

Source record
DIN 00248843: PVF-K 500 Raw flags: notABenefit=Y, sec3=Y Item: 081216034; group id 29; item number 0061; lccId None; manufacturer id FRS Source form: Tab; strength: 300mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00248843 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1484
Interchangeable products
PEN V-K · DIN 00642215 · $0.1873
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00248843
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since April 21, 1998 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (J01C): coverage varies; not interchangeable

  • Amoxicillin (Novamoxin): general benefit, not a benefit, listing status unconfirmed
  • Amoxicillin + clavulanic acid (Clavulin): general benefit, not a benefit
  • Ampicillin (Penbritin): general benefit, not a benefit
  • Cloxacillin (Orbenin): general benefit, not a benefit
  • Piperacillin + tazobactam (Tazocin): not a benefit
Other drugs in the same formulary class (08:12:16 Penicillins) and how they are covered

Matched class: 08:12:16 Penicillins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Some products covered without a code (check the product listing): AMOXICILLIN, AMOXICILLIN & CLAVULANIC ACID, AMPICILLIN, CLOXACILLIN 08:12:16 Penicillins

AMOXICILLIN

· 36 products · General benefit (27), Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (4), Temporary benefit (1) · strengths: 250mg, 500mg, 125mg, 25mg/mL, 50mg/mL · Cap, Chew Tab, O/L, Pd for Oral Susp

AMOXICILLIN & CLAVULANIC ACID

· 25 products · General benefit (22), Listed, not a benefit (3) · strengths: 25mg & 6.25mg/mL, 50mg & 12.5mg/mL, 200mg & 28.5mg/5mL, 400mg & 57mg/5mL, 250mg & 125mg, 500mg & 125mg, 875mg & 125mg · O/L, Susp, Tab

AMPICILLIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 250mg, 500mg · Cap

CLOXACILLIN

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 250mg, 500mg, 25mg/mL · Cap, O/L

PIPERACILLIN SODIUM & TAZOBACTAM SODIUM

· 18 products · Off-Formulary Interchangeable, not an ODB benefit (16), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2) · strengths: 2g & 250mg, 3g & 375mg, 4g & 500mg · Inj Pd-2.25g Vial Pk, Inj Pd-3.375g Vial Pk, Inj Pd-4.5g Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:12:16
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: moderately infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CEFUROXIME AXETIL · General benefit (7), Listed, not a benefit (2) Indications CEFTIN (cefuroxime axetil for oral suspension) is indicated for the treatment of patients with mild to moderately severe infections caused by susceptible strains of the designated organisms in the following diseases: • Upper Respiratory Tract Infections: Pharyngitis and tonsillitis caused by Streptococcus pyogenes. PM: https://pdf.hres.ca/dpd_pm/00081954.PDF; date 2025-10-03; DIN 02212307; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1. Indications PEN-VK (Penicillin V Potassium (Phenoxymethylpenicillin Potassium)) is indicated for: • Mild to moderately severe infections caused by penicillin V sensitive microorganisms including streptococcal pharyngitis, staphylococcal infection without bacteremia and pneumococcal infections. Therapy should be guided by bacteriologic sensitivity tests and clinical response. Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with potassium phenoxymethyl penicillin during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of potassium phenoxymethyl penicillin: • Streptococcal infections (without bacteremia): Mild to moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. Note: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. • Pneumococcal infections: Mild to moderately severe infections of the respiratory tract. • Staphylococcal infections sensitive to penicillin V: Mild infections of the… https://pdf.hres.ca/dpd_pm/00081311.PDF PM date: August 1, 2025 Source product: PEN-VK; DIN 00642215; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Nadopen-V, PVF-K 500: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026